Market Closed -
Hong Kong S.E.
03:08:30 2023-11-22 EST
|
5-day change
|
1st Jan Change
|
5.62
HKD
|
-0.71%
|
|
-.--%
|
-.--%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
13,555
|
28,141
|
10,561
|
5,515
|
2,258
|
2,258
|
-
|
Enterprise Value (EV)
1 |
11,288
|
25,422
|
7,611
|
4,432
|
2,183
|
2,383
|
2,721
|
P/E ratio
|
-27.5
x
|
-148
x
|
-28.4
x
|
-5.2
x
|
-3.13
x
|
-7.16
x
|
-11.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
58.1
x
|
102
x
|
25.4
x
|
13.6
x
|
4.6
x
|
3.07
x
|
2.39
x
|
EV / Revenue
|
48.4
x
|
92.1
x
|
18.3
x
|
10.9
x
|
4.44
x
|
3.24
x
|
2.88
x
|
EV / EBITDA
|
-37.7
x
|
-180
x
|
-33.5
x
|
-8
x
|
-4.62
x
|
-9.91
x
|
-25
x
|
EV / FCF
|
-34,433,168
x
|
-70,410,129
x
|
-13,623,027
x
|
-
|
-2,500,431
x
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-
|
-0%
|
-
|
-
|
Price to Book
|
3.43
x
|
7.22
x
|
2.32
x
|
-
|
0.78
x
|
-
|
-
|
Nbr of stocks (in thousands)
|
404,469
|
422,969
|
437,897
|
437,897
|
437,897
|
437,897
|
-
|
Reference price
2 |
33.51
|
66.53
|
24.12
|
12.59
|
5.157
|
5.157
|
5.157
|
Announcement Date
|
3/27/20
|
3/31/21
|
3/31/22
|
3/31/23
|
3/28/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
233.3
|
276
|
415.9
|
406.5
|
491.4
|
735.3
|
946
|
EBITDA
1 |
-299.1
|
-140.9
|
-227
|
-553.7
|
-471.9
|
-240.4
|
-108.9
|
EBIT
1 |
-328
|
-178.6
|
-278.6
|
-666
|
-596.7
|
-358.3
|
-
|
Operating Margin
|
-140.63%
|
-64.7%
|
-67%
|
-163.86%
|
-121.44%
|
-48.72%
|
-
|
Earnings before Tax (EBT)
1 |
-381.5
|
-185.8
|
-377.6
|
-1,156
|
-752.5
|
-392.5
|
-
|
Net income
1 |
-380.7
|
-182
|
-373.6
|
-1,058
|
-720.9
|
-316.4
|
-
|
Net margin
|
-163.21%
|
-65.93%
|
-89.85%
|
-260.22%
|
-146.71%
|
-43.02%
|
-
|
EPS
2 |
-1.220
|
-0.4500
|
-0.8500
|
-2.420
|
-1.650
|
-0.7200
|
-0.4500
|
Free Cash Flow
|
-327.8
|
-361.1
|
-558.7
|
-
|
-872.9
|
-
|
-
|
FCF margin
|
-140.53%
|
-130.79%
|
-134.35%
|
-
|
-177.65%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/27/20
|
3/31/21
|
3/31/22
|
3/31/23
|
3/28/24
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
---|
Net sales
1 |
147.1
|
102
|
174
|
239.3
|
176.6
|
210
|
196.5
|
255.6
|
235.8
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-
|
-
|
-60.08
|
-218.6
|
-234.2
|
-431.8
|
-329.3
|
-267.5
|
Operating Margin
|
-
|
-
|
-
|
-25.11%
|
-123.77%
|
-111.54%
|
-219.77%
|
-128.82%
|
-113.45%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-
|
-
|
-0.2600
|
-0.5900
|
-0.4600
|
-1.960
|
-0.8000
|
-0.8500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/27/20
|
8/28/20
|
3/31/21
|
8/31/21
|
3/31/22
|
8/31/22
|
3/31/23
|
8/31/23
|
3/28/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
125
|
463
|
Net Cash position
1 |
2,267
|
2,720
|
2,950
|
1,083
|
75.7
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.5206
x
|
-4.251
x
|
Free Cash Flow
|
-328
|
-361
|
-559
|
-
|
-873
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-21.8%
|
-5.07%
|
-8.94%
|
-25.4%
|
-21.6%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-16.2%
|
-4.35%
|
-7.93%
|
-19.9%
|
-14.5%
|
-
|
-
|
Assets
1 |
2,352
|
4,180
|
4,714
|
5,303
|
4,966
|
-
|
-
|
Book Value Per Share
|
9.760
|
9.220
|
10.40
|
-
|
6.620
|
-
|
-
|
Cash Flow per Share
|
-0.9800
|
-0.5800
|
-1.040
|
-
|
-1.390
|
-
|
-
|
Capex
|
24.5
|
124
|
102
|
-
|
263
|
-
|
-
|
Capex / Sales
|
10.52%
|
44.94%
|
24.47%
|
-
|
53.5%
|
-
|
-
|
Announcement Date
|
3/27/20
|
3/31/21
|
3/31/22
|
3/31/23
|
3/28/24
|
-
|
-
|
Last Close Price
5.157
CNY Average target price
8.288
CNY Spread / Average Target +60.73% Consensus |
1st Jan change
|
Capi.
|
---|
| -.--% | 315M | | +10.87% | 127B | | -8.56% | 10.76B | | -21.01% | 7.06B | | +50.07% | 6.5B | | -34.16% | 3.99B | | +8.50% | 3.44B | | -20.67% | 2.45B | | -19.70% | 1.89B | | -22.48% | 1.75B |
Medical Devices & Implants
|